Josephine van Dongen

3 Updated cost-effectiveness and risk-benefit analysis 75 16. Schurink-van’ t Klooster TM, de Melker HEE.The national immunisation programme in the Netherlands: surveillance and developments in 2015-2016. Bilthoven: Rijksinstituut voor Volksgezondheid en Milieu; 2016. 17. Mangen MJ, van DuynhovenYT,Vennema H, van Pelt W, Havelaar AH, de Melker HE. Is it cost-effective to introduce rotavirus vaccination in the Dutch national immunization program? Vaccine. 2010;28(14):2624–35. 18. van Dongen F, Schuurman R, Bonten MJM, Study-Group ObotR. Rotavirus hospitalizations in the absence of rotavirus vaccine in 2015–2016 in the Netherlands. In: 5th European Exper t Meeting on Rotavirus Vaccination: March 20-22nd, 2017 2017; Utrecht; 2017. p. 85. 19. RIVAR-project: Risk-Group Infant Vaccination Against Rotavirus. [http://portal. juliuscentrum.nl/research/nl-NL/cohor tsandprojects/cohortsprojects/rivar.aspx]. 20. Marlow R, Finn A,Trotter C. Quality of life impacts from rotavirus gastroenteritis on children and their families in the UK. Vaccine . 2015;33(39):5212–6. 21. Quee F, de Hoog MLA, Schuurman R, Bruijning-Verhagen P. A comparison of incidence, transmission and burden of norovirus and rotavirus infections among young families in the Netherlands. In: 5th European Exper t Meeting on Rotavirus Vaccination: March 20-22nd, 2017 2017; Utrecht; 2017. p. 83–4. 22. ZIN. Kostenhandleiding: Methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidszorg. Diemen: Zorginstituut Nederland (ZIN); 2015. Geactualiseerde versie 2015 23. Prelog M, Gor th P, Zwazl I, Kleines M, Streng A, Zlamy M, Heinz-Erian P,Wiedermann U. Universal mass vaccination against rotavirus: indirect effects on rotavirus infections in neonates and unvaccinated young infants not eligible for vaccination. J Infect Dis . 2016;214(4):546–55. 24. Atchison CJ, Stowe J, Andrews N, Collins S, Allen DJ, Nawaz S, Brown D, Ramsay ME, Ladhani SN. Rapid declines in age group-specific rotavirus infection and acute gastroenteritis among vaccinated and unvaccinated individuals within 1 year of rotavirus vaccine introduction in England andWales. J Infect Dis. 2016;213(2):243–9. 25. Krishnarajah G, Demissie K, Lefebvre P, Gaur S, Sheng Duh M. Clinical and cost burden of rotavirus infection before and after introduction of rotavirus vaccines among commercially and Medicaid insured children in the United States. Hum Vaccin Immunother. 2014;10(8):2255–66. 26. Kaufman HW, Chen Z.Trends in laboratory rotavirus detection: 2003 to 2014. Pediatrics. 2016;138(4):e20161173. 27. Sabbe M, Berger N, Blommaer t A, Ogunjimi B, Grammens T, Callens M,Van Herck K, Beutels P,Van Damme P, Bilcke J. Sustained low rotavirus activity and hospitalisation rates in the post-vaccination era in Belgium, 2007 to 2014. Euro Surveill. 2016;21 28. Veldwijk J, Lambooij MS, Bruijning-Verhagen PC, Smit HA, deWit GA. Parental preferences for rotavirus vaccination in young children: a discrete choice experiment. Vaccine. 2014;32(47):6277–83. 29. Zorginstituut Nederland. Medicijnkosten.nl. [https://www.medicijnkosten.nl/ databank?artikelId=7083&hoeveelheid=1,00]. 30. Nederlandse Zorgautoriteit.Toedieningskosten per vaccinatie - H006: neventarief 0 tot 5 jarige - Nederlandse Zorgautoriteit Rekenstaat 2014 tariefbeschikking. Utrecht: Nederlandse Zorgautoriteit; 2014. 31. Rozenbaum MH, Mangen MJ, Giaquinto C,Wilschut JC, Hak E, Postma MJ, Consensus Group on Dutch Rotavirus V. Cost-effectiveness of rotavirus vaccination in the Netherlands; the results of a consensus model. BMC Public Health . 2011;11:462.